Viking Therapeutics (VKTX) Equity Average (2016 - 2025)
Viking Therapeutics (VKTX) has disclosed Equity Average for 11 consecutive years, with $676.0 million as the latest value for Q4 2025.
- Quarterly Equity Average fell 24.54% to $676.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $676.0 million through Dec 2025, down 24.54% year-over-year, with the annual reading at $759.7 million for FY2025, 23.65% up from the prior year.
- Equity Average hit $676.0 million in Q4 2025 for Viking Therapeutics, down from $754.2 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $927.4 million in Q2 2024 to a low of $139.7 million in Q1 2023.
- Historically, Equity Average has averaged $460.1 million across 5 years, with a median of $309.2 million in 2023.
- Biggest five-year swings in Equity Average: fell 28.53% in 2022 and later soared 358.97% in 2024.
- Year by year, Equity Average stood at $207.5 million in 2021, then decreased by 28.53% to $148.3 million in 2022, then soared by 141.62% to $358.3 million in 2023, then skyrocketed by 150.01% to $895.9 million in 2024, then fell by 24.54% to $676.0 million in 2025.
- Business Quant data shows Equity Average for VKTX at $676.0 million in Q4 2025, $754.2 million in Q3 2025, and $821.2 million in Q2 2025.